Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ACADEMIA
ACADEMIA
- Chiba Univ. Finds Dropout Rates of 60-80% in Secondary Endpoints, Raps VART Study as “Absolutely Unreliable”
July 16, 2014
- 60% of Pharmacists Recognize Authorized Generics: Survey
July 15, 2014
- Uniform Brand Names for Four More Generic Combination Drugs Announced
July 15, 2014
- Whistle-Blower Insists There Were Willful Data Falsifications in J-ADNI Project
July 9, 2014
- NCC Sets Up Rare Cancer Center, Eying Clinical Studies
July 1, 2014
- University of Tokyo Admits Inappropriate Patient Data Corrections in J-ADNI
June 25, 2014
- Univ. Says Data Leaks in SIGN Run Afoul of Personal Information Law, Newly Finds Bristol’s Misconduct
June 25, 2014
- Once-Weekly Trelagliptin Shows Non-Inferiority to Once-Daily Alogliptin in PIII Study
June 24, 2014
- National University Hospital Council Announces Guidelines on Disclosure of Funding
June 23, 2014
- Joint Committee Organized by Four Scientific Societies Urges Caution in the Use of Diamox as a Reagent
June 23, 2014
- Hokkaido University to Begin Clinical Study of Novel Cancer Diagnostic Imaging Agent
June 23, 2014
- Kitasato Univ. Doctor Urges Psychiatry Society to Create Penalties on Undeclared COI
June 13, 2014
- Acofide Shows Repeated Difference against Placebo in Controlled Studies: Prof. Miwa of Hyogo College of Medicine
June 10, 2014
- JSH’s Committee Calls for Guidelines to Clarify Relations Between Companies, Research Institutions
June 3, 2014
- VART Study Lead Investigator to Discuss with Co-Authors, Mull Paper Retractions
May 28, 2014
- Eisai Responds to Media Report of Allegations of Data Falsification in J-ADNI Study
May 28, 2014
- Chiba Univ. Advises Authors to Withdraw VART Papers
May 26, 2014
- Sapporo Hospital Sorry for Ethical Guidelines Violations in Nesp Clinical Study
May 19, 2014
- Chiba University Hospital Suspends Use of Novartis’s Products in Response to Scandal over VART Study
May 12, 2014
- Careful Approach Needed in Legislating for Clinical Research: JAMS Pres.
May 8, 2014
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…